Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.Haematologica|April 21, 2019
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative studySabine Kayser, Robert K Hills, Marlise R Luskin, et al.Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.Biorxiv : the Preprint Server for Biology|July 14, 2025
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosisJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.Pageof 12